A funded organoid and PDX panel as the go/no-go gate before IND-enabling money
Before any academic compound gets money for pre-trial studies, it would have to show activity in a standard panel of patient-derived tumour models run by an independent centre, so weak candidates are stopped early.
A central facility maintains a standardised, molecularly characterised panel of patient-derived organoids and xenografts across cancer types (drawing on EurOPDX, the NCI Patient-Derived Models Repository and Human Cancer Models Initiative collections) and tests every candidate nominated for IND-enabling funding in a blinded, pre-registered protocol with clinically relevant exposure. Results are published regardless of outcome. Funding for toxicology and CMC is contingent on passing pre-agreed activity criteria. This replaces the variable, investigator-run efficacy evidence that currently supports translational decisions.
- The valley of death between lab and product · Most academic discoveries die before anyone tests them in people because nobody funds the middle step.
- Preclinical models that do not predict people · Nine in ten cancer drugs that work in mice fail in humans. Our models are the reason.
Pages like this
not linked directly; found by shared links- IdeaAn open model bank for the rare tumours nobody has models for
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Functional (ex vivo) drug testing, Patient-derived organoids.
- IdeaRun the mouse or organoid trial at the same time as the human trial
Shares Patient-derived organoids to pick ADC payloads, Patient-derived xenografts, Functional (ex vivo) drug testing, Patient-derived organoids.
- IdeaMake in vivo metastasis screens a required step in drug discovery
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids, Preclinical models that do not predict people.
- IdeaShared reference organoid and PDX panels that every lab can test against
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids, Preclinical models that do not predict people.
- IdeaAutomated combination discovery: patient-sample screens feeding Bayesian platform trials
Shares Patient-derived organoids to pick ADC payloads, Functional (ex vivo) drug testing, Patient-derived organoids, Preclinical models that do not predict people.
- IdeaScore every preclinical model by how often it predicted the clinical result
Shares Cancer Models (PDCM Finder) & HCMI, Patient-derived xenografts, Patient-derived organoids, Preclinical models that do not predict people.
- IdeaAn independent replication institute that re-tests key preclinical cancer findings before trials
Shares Patient-derived xenografts, Patient-derived organoids, The valley of death between lab and product.
- IdeaZebrafish avatars for a drug answer within a week
Shares Patient-derived xenografts, Functional (ex vivo) drug testing, Preclinical models that do not predict people.